Granulocyte-macrophage colony-stimulating factor messenger RNA (CSF2 mRNA) (CSF2 mRNA)

Granulocyte-macrophage colony-stimulating factor messenger RNA (CSF2 mRNA) is the genetic template for the synthesis of the GM-CSF cytokine, a critical regulator of the innate and adaptive immune systems [1]. This mRNA is characterized by a highly regulated 3' untranslated region containing AU-rich elements (AREs), which serve as binding sites for RNA-binding proteins like tristetraprolin that control its stability and translation rate [2]. In healthy individuals, CSF2 mRNA is transiently expressed to stimulate the production and activation of myeloid cells like macrophages and neutrophils during infection [3]. However, chronic stabilization or overexpression of CSF2 mRNA is linked to the pathogenesis of inflammatory diseases such as rheumatoid arthritis and multiple sclerosis, where excess GM-CSF drives tissue damage [4]. While most current clinical therapies target the GM-CSF protein or its receptor, CSF2 mRNA is an emerging target for RNA-based therapeutics, including siRNAs and antisense oligonucleotides, designed to reduce cytokine levels at the source [5]. Therapeutic modulation of this target must be carefully managed, as total loss of GM-CSF function can lead to pulmonary alveolar proteinosis due to impaired surfactant clearance by alveolar macrophages [6].

Other names

GM-CSF mRNAColony stimulating factor 2 (granulocyte-macrophage) mRNACSF2 transcript

RNA interference and antisense-mediated degradation of the mRNA transcript to prevent translation of the GM-CSF protein.